Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera ...
Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...
The share-swap ratio has been fixed at 70.28 Biocon shares for every 100 Biocon Biologics shares, at a share price of Rs ...
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...
Clinical Trials Arena on MSN
Daiichi Sankyo announces first patient dosed in phase III trial of Enhertu
Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, ...
FiscalNote Holdings, Inc. ("FiscalNote"), a leading provider of AI-driven policy and regulatory intelligence solutions, today announced that members of the senior management team will be participating ...
MARION, NORTH CAROLINA / ACCESS Newswire / December 9, 2025 / Greene Concepts Inc. , owner and operator of a ...
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing ...
FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results ...
A recent clinical trial found that a new TROP2-targeted antibody-drug conjugate (ADC) showed encouraging efficacy in treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback